Business Wire

ONE-IBC-GROUP

23.3.2022 10:02:14 CET | Business Wire | Press release

Share
One IBC Group Focuses on Digital Transformation and Innovation in the Corporate Service Industry

One IBC Group , an international corporate service provider with 12 years of experience and a global outreach, highlighted in its 2022 action plan that technology is going to be the company’s main focus of growth. Through digital transformation and innovation, One IBC Group believes not only its services and operations will drastically improve, but the whole industry will also benefit and change the way it traditionally works.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220323005053/en/

The quest for digital transformation

In recent years, a majority of businesses have shifted their focus on technology and innovation in order to improve operational efficiency and further connect their services to their customers. With the help of revolutionary technologies such as CRMs, mobile apps, websites, etc., businesses have now been able to simplify their operations, tailor their products and services, and adapt to the various needs of their clients.

With that being said, not every industry can embark on the digitalized trend as quickly. Corporate service is a good example. Most, if not all, corporate service providers on the market right now are still using the same technology of 20 years ago. Though the services can be processed entirely remotely, and some can even be done automatically, no significant change has been made since then, while customer demand is increasing from time to time.

For an industry that has so much potential for digital transformation, corporate service is looking for a game-changing breakthrough.

One IBC Group’s plan to innovate

Since it was founded, One IBC Group has been using technology to remotely provide corporate services around the world. To be able to grow faster and compete with big players in the industry, the company decided to focus more on technology development.

In its 2022 action plan, One IBC Group emphasizes that digital transformation and innovation will be its primary mission. The plan set out a 5-year roadmap pinpointing each goal that needed to be achieved in a set time to upgrade the system and apply new technology. It includes automating the service order process, optimizing the operation procedures, building a client portal, incorporating software-as-a-service (SaaS) platforms, and constantly updating the whole system.

“It is no longer the future. The race for innovation is the new norm now,” said Jimmy Lee, CEO of One IBC Group. “With a solid technology foundation that we are having now, we believe One IBC Group can make a revolution in the corporate service industry.”

Prior to that, in 2021, One IBC Group had introduced its first mobile app . It was created with the goal of enhancing and improving client experience as well as introducing a new way to set up overseas businesses.

“This is just the beginning,” Jimmy said. “We are trying to provide more services and integrate them into our platforms as part of our ongoing development and extension, at the same time create a whole ecosystem for businesses to build their global expansion strategies.”

About One IBC Group

One IBC Group is a leading corporate service provider with global experience and delivery capabilities.

Since its beginning, One IBC Group has strived to provide global expansion strategies to entrepreneurs, investors, and business owners worldwide, with services ranging from company formation , trademark and license registration , to office and secretarial services. It has been building connections with international partners and using advanced technology to provide the best services to its clients.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye